Aksys set to launch daily haemodialysis home system
This article was originally published in Clinica
Executive Summary
We don't treat high blood pressure three times a week, why do we dialyse people three times a week? We don't let diabetes go untreated for two or three days, yet we let end-stage renal disease (ESRD) patients go two or three days without treatment." Speaking at the US Bancorp Piper Jaffray healthcare conference in New York last month, William Dow, president and CEO of Aksys, outlined the case for more frequent dialysis, referring to his company's personal haemodialysis system (PHD) designed to offer daily treatment in the home.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.